In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant (pre-operative) pembrolizumab.
As Steward Ship Was Sinking, CEO Bought $40M Yacht
Welcome to the latest edition of Investigative Roundup, highlighting some of the best investigative reporting on healthcare each week. As Steward Ship Was Sinking, CEO